Hormonal Maintenance Tx Ups PFS in Low-Grade Serous Cancer

This article originally appeared here.
Share this content:
Hormonal Maintenance Tx Ups PFS in Low-Grade Serous Cancer
Hormonal Maintenance Tx Ups PFS in Low-Grade Serous Cancer

MONDAY, Feb. 27, 2017 (HealthDay News) -- For women with low-grade serous carcinoma of the ovary or peritoneum, hormonal maintenance therapy (HMT) is associated with improved progression-free survival (PFS), according to a study published online Feb. 21 in the Journal of Clinical Oncology.

David M. Gershenson, M.D., from the University of Texas MD Anderson Center in Houston, and colleagues compared PFS and overall survival associated with HMT versus routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy for 203 women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum. Overall, 133 patients underwent OBS and 70 received HMT.

The researchers found that the median PFS was 26.4 and 64.9 months for patients who underwent OBS and HMT, respectively (P < 0.001). Overall survival did not differ significantly between the two groups (102.7 versus 115.7 months, respectively; P = 0.42). The median PFS was superior for patients who received HMT for subgroups of women who were disease free (81.1 versus 30.0 months; P < 0.001) or had persistent disease (38.1 versus 15.2 months; P < 0.001). Compared with women who underwent OBS, those who received HMT had a significantly lower risk of disease progression (hazard ratio, 0.44; 95 percent confidence interval, 0.31 to 0.64; P < 0.001).

"Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatment had significantly longer PFS compared with women who underwent OBS," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »